The Alzheimer’s disease (AD) medication market is set to gravitate toward therapies capable of arresting or slowing the disease progression. As the currently marketed drugs provide only symptomatic alleviation, the AD medication market offers ample opportunities for growth, in particular for drugs that can modify the course of the disease.
New analysis from Frost & Sullivan (pharmaceuticals.frost.com), U.S. Alzheimer’s Disease Medication Markets, finds that the market earned revenues of $2.41 billion in 2006 and estimates this to exceed $4.00 billion in 2013.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Alzheimer’s Disease Medication Markets, then send an e-mail to Melina Trevino - Corporate Communications at email@example.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via email upon receipt of the above information.
“The potential of this unmet needs market has attracted considerable attention from drug developers,” notes Frost & Sullivan Research Analyst Adriana Rusu. “The first wave of disease modifying drugs is likely to reach the market within the next couple of years, and in combination with symptomatic drugs, could enhance treatment options in this growing market.”
Demand for AD medication is set to increase with the rising disease prevalence resulting from the growing number of the baby-boomer population that will reach the age of 65 within the next several years. Simultaneously, an increased level of awareness about Alzheimer's, coupled with improved diagnostic techniques, are likely to expand the patient base and fuel market growth. Moreover, increased research and development activity is expected to expand the treatment options in the near future, and consequently the overall AD medication market.
Presently, due to patent protection, only branded drugs are available to treat Alzheimer’s. However, the competitive landscape is expected to soon change as their patent expiration dates are nearing. With the possibility of generics reaching the market by 2009, competition in the AD medication market is likely to intensify. Consequently, the availability of less expensive generics is expected to temporarily restrain market growth, before the new disease-modifying drugs are able to establish a strong market presence.
Manufacturers of existing drugs, which are facing pending generic erosion, can distinguish their products in particular through new drug delivery methods and formulations. Given the special needs of the AD patient population, such strategies are most likely to appeal to end users and have a market impact.
However, the developers of new drugs are facing different challenges. For drugs in development, time-to-market is critical to seize the opportunity provided by the high needs of this market. “Designing and conducting effective clinical trials that could ensure successful outcomes and compelling results may accelerate the time-to-market and aid in establishing a solid competitive advantage,” concludes Rusu.
U.S. Alzheimer’s Disease Medication Markets is part of the Pharmaceutical and Biotechnology Growth Partnership Service Program, which includes research services in the following markets: U.S. Generic Pharmaceuticals, U.S. Multiple Myeloma, and U.S. COPD: Therapeutic Overview and Patient Outlook. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews with the press are available.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership service, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective, and combines ongoing analysis of markets, technologies, econometrics, and demographics.